HAEMONETICS CORP — Director's Dealing 2018

Jun 13, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2018-06-11

Reporting Person: Bolorforosh Said (EVP, Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-11	Common Stock	A	935	—	Acquired	935	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-11	Non-qualified Stock Option (Right to Buy)	$93.52	A	3330	Acquired	2025-06-11	Common Stock (3330)	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.